Skip to main content
SpringerLink
Log in

Calcineurin Inhibitors

  • Chapter
Vitiligo

  • 1718 Accesses

Abstract

The topical calcineurin inhibitors — tacrolimus ointment 0.1 and 0.03% (FK 506, Protopic®, Astellas) and pime-crolimus cream 1% (SDZ ASM 981, Elidel®, Novartis) — have been specifically developed for the treatment of inflammatory skin diseases, and approved for the short-term and intermittent long-term treatment of atopic dermatitis in several countries (including the United States of America and European Union nations) [12, 19, 28, 32, 34, 38]. In contrast to topical steroid, they do not have the risk of local side effects, such as skin atrophy, telangiectasia, and glaucoma after prolonged use. Therefore, they are preferentially used in areas more susceptible to these side effects, such as head and neck region, flexures and genital area [23, 35]. Furthermore, because of the limited percutaneous penetration, signifi-cant systemic absorption has not been reported following normal use [1]. However, they are currently much more expensive than topical steroids.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Allen A, Siegfried E, Silverman R et al (2001) Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 137:747–750

    PubMed  CAS  Google Scholar 

  2. Almeida P, Borrego L, Rodriguez-Lopez J et al (2005) [Vitiligo. Treatment of 12 cases with topical tacrolimus]. Actas Dermosifiliogr 96:159–163

    Article  PubMed  Google Scholar 

  3. Bakos L, Bakos RM (2007) Focal acne during topical tac-rolimus therapy for vitiligo. Arch Dermatol 143:1223–1224

    PubMed  Google Scholar 

  4. Bieber T, Cork M, Ellis C et al (2005) Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 211:77–78

    Article  PubMed  CAS  Google Scholar 

  5. Bilac DB, Ermertcan AT, Sahin MT, Ozturkcan S (2009) Two therapeutic challenges: facial vitiligo successfully treated with 1% pimecrolimus cream and 0.005% calcipot-riol cream. J Eur Acad Dermatol Venereol 23:72–73

    Article  PubMed  CAS  Google Scholar 

  6. Boone B, Ongenae K, Van Geel N et al (2007) Topical pime-crolimus in the treatment of vitiligo. Eur J Dermatol 17:55–61

    PubMed  CAS  Google Scholar 

  7. Castanedo-Cazares JP, Lepe V, Moncada B (2003) Repigmentation of chronic vitiligo lesions by following tac-rolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed 19:35–36

    Article  PubMed  CAS  Google Scholar 

  8. Coskun B, Saral Y, Turgut D (2005) Topical 0.05% clobeta-sol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 15:88–91

    PubMed  Google Scholar 

  9. Dawid M, Veensalu M, Grassberger M, Wolff K (2006) Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, doubleblind, vehicle-controlled study. J Dtsch Dermatol Ges 4:942–946

    Article  PubMed  Google Scholar 

  10. De D, Kanwar AJ (2008) Tacrolimus-induced hyperpigmen-tation in a patch of vitiligo. Skinmed 7:93–94

    Article  PubMed  Google Scholar 

  11. Fai D, Cassano N, Vena GA (2007) Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol 21:916–920

    Article  PubMed  CAS  Google Scholar 

  12. Fleischer AB, Ling M, Eichenfield L et al (2002) Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 47:562–570

    Article  PubMed  Google Scholar 

  13. Grimes PE, Morris R, Avaniss-Aghajani E et al (2004) Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 51:52–61

    Article  PubMed  Google Scholar 

  14. Grimes PE, Soriano T, Dytoc MT (2002) Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 47:789–791

    Article  PubMed  Google Scholar 

  15. Hartmann A, Brocker EB, Hamm H (2008) Occlusive t nhances efficay of tacrolimus 0.1% oinement in adult patients with vitiligo: results of a placebo-controlled 12 month prospective study. Acta Derm venereol 88:474–479

    Article  PubMed  CAS  Google Scholar 

  16. Kang HY, Choi YM (2006) FK506 increases pigmentation and migration of human melanocytes. Br J Dermatol 155:1037–1040

    Article  PubMed  CAS  Google Scholar 

  17. Kanwar AJ, Dogra S, Parsad D (2004) Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol 29:589–592

    Article  PubMed  CAS  Google Scholar 

  18. Kawalek AZ, Spencer JM, Phelps RG (2004) Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 30:130–135

    Article  PubMed  Google Scholar 

  19. Kostovic K, Pasic A (2005) New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs 65:447–459

    Article  PubMed  CAS  Google Scholar 

  20. Lan CC, Chen GS, Chiou MH et al (2005) FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 153:498–505

    Article  PubMed  CAS  Google Scholar 

  21. Lepe V, Moncada B, Castanedo-Cazares JP et al (2003) A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 139:581–585

    Article  PubMed  CAS  Google Scholar 

  22. Mayoral FA, Gonzalez C, Shah NS, Arciniegas C (2003) Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 207:322–323

    Article  PubMed  Google Scholar 

  23. Mayoral FA, Vega JM, Stavisky H et al (2007) Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo. J Drugs Dermatol 6:517–521

    PubMed  Google Scholar 

  24. Mehrabi D, Pandya AG (2006) A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 142:927–929

    PubMed  Google Scholar 

  25. Ormerod AD (2005) Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 153:701–705

    Article  PubMed  CAS  Google Scholar 

  26. Ostovari N, Passeron T, Lacour JP, Ortonne JP (2006) Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 142:252–253

    Article  PubMed  Google Scholar 

  27. Passeron T, Ostovari N, Zakaria W et al (2004) Topical tac-rolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 140:1065–1069

    Article  PubMed  CAS  Google Scholar 

  28. Qureshi AA, Fischer MA (2006) Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol 142:633–637

    Article  PubMed  Google Scholar 

  29. Sardana K, Bhushan P, Kumar Garg V (2007) Effect of tac-rolimus on vitiligo in absence of UV radiation exposure. Arch Dermatol 143:119–120

    PubMed  Google Scholar 

  30. Seirafi H, Farnaghi F, Firooz A et al (2007) Pimecrolimus cream in repigmentation of vitiligo. Dermatology 214:253–259

    Article  PubMed  Google Scholar 

  31. Sendur N, Karaman G, Sanic N, Savk E (2006) Topical pimecrolimus: a new horizon for vitiligo treatment? J Dermatolog Treat 17:338–342

    Article  PubMed  CAS  Google Scholar 

  32. Silverberg NB, Lin P, Travis L et al (2004) Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 51:760–766

    Article  PubMed  Google Scholar 

  33. Smith DA, Tofte SJ, Hanifin JM (2002) Repigmentation of vitiligo with topical tacrolimus. Dermatology 205:301–303

    Article  PubMed  CAS  Google Scholar 

  34. Soter NA, Fleischer AB, Webster GF et al (2001) Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 44:S39–S46

    Article  PubMed  CAS  Google Scholar 

  35. Souza Leite RM, Craveiro Leite AA (2007) Two therapeutic challenges: periocular and genital vitiligo in children successfully treated with pimecrolimus cream. Int J Dermatol 46:986–989

    Article  PubMed  Google Scholar 

  36. Tanghetti EA () Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 71:158–162

    Google Scholar 

  37. Travis LB, Weinberg JM, Silverberg NB (2003) Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 139:571–574

    Article  PubMed  Google Scholar 

  38. Wolff K (2005) Pimecrolimus 1% cream for the treatment of atopic dermatitis. Skin Therapy Lett 10:1–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Ghent University Hospital, Ghent, Belgium

    N. Van Geel, B. Boone, I. Mollet & J. Lambert

Authors
  1. N. Van Geel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Boone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Mollet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Van Geel .

Editor information

Editors and Affiliations

  1. Istituto Dermatologico San Gallicano, via Elio Chianesi 53, Roma, 00144, Italy

    Mauro Picardo

  2. Service de Dermatologie De Dermatologie Pédiatrique, Centre de référence des maladies rares de la Peau Hôpital Saint-André, 1 rue Jean Burguet, Bordeaux, 33000, France

    Alain Taïeb

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Van Geel, N., Boone, B., Mollet, I., Lambert, J. (2010). Calcineurin Inhibitors. In: Picardo, M., Taïeb, A. (eds) Vitiligo. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69361-1_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-69361-1_39

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-69360-4

  • Online ISBN: 978-3-540-69361-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation